+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

N

Actively Recruiting

Researchers are conducting a multicenter, observational study in Italy to collect detailed information on patients with bone metastases. The study aims to establish a national database to better understand clinical and biological factors related to primary tumors and their bone metastases. This research will also evaluate the impact of treatments and care pathways on skeletal events over a period of up to 15 years. Patients with bone metastases from solid tumors will be enrolled in this study and registered in a specialized online database. Each participant will be followed from enrollment until death or until they stop follow-up for other reasons. The study does not involve any experimental treatments but collects comprehensive data on patients conditions and care. Participants will provide informed consent and their medical data will be regularly recorded and analyzed. The study monitors clinical outcomes, skeletal-related events, and the efficiency of treatment pathways. Data collection will continue for up to 15 years, providing long-term insights into bone metastases and patient management.

Age: 18Years +All Genders
30 locations
C

Actively Recruiting

Researchers are evaluating treatments for small cell lung cancer SCLC patients to determine if brain magnetic resonance imaging MRI surveillance alone is not worse than prophylactic cranial irradiation PCI combined with brain MRI surveillance in terms of overall survival. This phase III study also examines cognitive failure-free survival, quality of life, and safety between these two approaches. The study includes patients with limited and extensive stages of SCLC who have completed standard therapy without disease progression. Participants are randomly assigned to one of two groups. One group receives prophylactic cranial irradiation at 25 Gy in 10 fractions to the whole brain along with scheduled brain MRIs before randomization and at 3, 6, 9, 12, 18, and 24 months. The other group undergoes active brain MRI surveillance on the same schedule without PCI. Clinical evaluations occur every 3 months, and extracranial imaging is performed as per physician discretion. During the study, participants undergo repeated brain MRIs, clinical evaluations, and imaging to monitor cancer progression and brain metastases. Researchers assess overall survival, cognitive function, quality of life, toxicity severity, and cost-effectiveness over 12 months. Blood samples are collected for biobanking. The total study duration extends up to April 2028, with ongoing monitoring of health status and adverse effects throughout participation.

Age: 18Years +All GendersPhase Not Applicable
55 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the clinical performance and long-term safety of scaffold implantation for patients with coronary artery disease in a real-world regional setting. This observational prospective study involves two networks of centers, including all cath-labs in Emilia-Romagna and centers from the MAGIC retrospective study. Investigators have agreed on specific indications and implantation strategies to ensure consistency across centers. The treatment being studied is the implantation of at least one scaffold device during percutaneous coronary intervention PCI. The study focuses on complete revascularization in patients under 65 years, long lesion revascularization especially in the left anterior descending artery, and spontaneous coronary dissection. Implantation strategies include mandatory predilation, precise sizing, avoiding vessels outside specific diameter ranges, and mandatory postdilation with a non-compliant balloon. Participants will be enrolled after approval and followed for safety and outcomes, with adverse events monitored continuously by a Data Safety Monitoring Board. All coronary angiographies and interventions are reviewed by an independent core laboratory to assess adherence to implantation techniques. The primary outcome measured is device-oriented cardiac events at one year, with study participation lasting at least one year to ensure follow-up and compliance.

Age: 18Years +All Genders
17 locations
G

Actively Recruiting

Researchers are comparing the study drug sacituzumab govitecan SG Trodelvy to standard treatments in people with extensive stage small cell lung cancer ES-SCLC who have already received prior therapy. The main goal is to see which treatment helps participants live longer by measuring overall survival. This is a global, randomized, open-label Phase 3 trial conducted to evaluate the effects of SG versus standard care in this patient population. Participants in the study are randomly assigned to one of two treatment groups. Group A receives sacituzumab govitecan intravenously at 10 mgkg on Days 1 and 8 of each 21-day cycle. Group B receives one of several approved standard treatments chosen by the investigator, including topotecan, lurbinectedin where available, or amrubicin in Japan, administered according to usual schedules in 21-day cycles. Treatment continues until disease worsens, unacceptable side effects occur, death, or other reasons for stopping treatment. During the study, participants undergo regular assessments including imaging scans to measure tumor response, physical evaluations, and laboratory tests to monitor safety. Researchers track important outcomes such as progression-free survival, response rates, duration of response, and quality of life measures related to breathing and physical function for up to 4.5 years. Safety is closely monitored by recording adverse events and laboratory abnormalities throughout the treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
219 locations
I

Actively Recruiting

Researchers are creating a large registry of patients with ATTR amyloidosis to better understand the diseases natural history in a real-world setting. This study aims to collect data from diagnosis and during follow-up to develop and validate models that predict outcomes and response criteria at any stage of the disease. The registry also promotes data sharing and collaboration among amyloidosis experts and physicians nationwide, improving diagnosis and management of systemic amyloidosis. The study involves an online registry tool accessible to healthcare providers, facilitating data entry and sharing. This network allows physicians to request diagnostic support from the Amyloidosis Research and Treatment Center ARTC, enhancing patient care through expert collaboration. The registry collects ongoing data during patient follow-up at participating centers. Participants contribute by allowing their clinical data to be included in the registry, either prospectively or retrospectively if they have given informed consent. Researchers will monitor the establishment and use of the online data-sharing tool over five years. The study does not involve experimental treatments but focuses on observation and data collection to improve understanding and management of ATTR amyloidosis.

Age: 18Years - 99YearsAll Genders
30 locations